Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development INDIANAPOLIS and EHIME, Japan, May 5, 2025 /PRNewswire/ -- ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

4D-150 continues to be well tolerated during up to three years of follow-up in all patients (n=71) treated with 3E10 vg/eye dose, with the highest 4D-150-related intraocular inflammation (SUN/NEI ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Choose from Biotech Stock stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Plans and pricing Video Back Videos home Signature collection ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

Creating diagrams that captivate an audience requires a blend of creativity and strategy. Diagrams are powerful tools for ...

The best stories published in the arts section from the 2024 to 2025 school year. True to form, Arts’ output for the year ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, ...